REFERENCES

  1. Prismaflex Operator’s Manual.
  2. M-Series Hemofilter Set Instructions for Use (IFU).
  3. HF-Series Hemofilter Set Instructions for Use (IFU).
  4. Kaplan AA. Dial Transplant. 2009;38:65.
  5. MARS Operating Instructions. 2015.
  6. Culley, C.M. et al., Implementing a standardized safety procedure for continuous renal replacement therapy solutions. American Journal of Health System Pharmacy, 2006; 63:756-63.
  7. Barletta, J.F., Resource Utilization and Total Cost of Commercially Available versus Manually Compounded Solutions Used for Dialysate in Continuous Renal Replacement Therapy. Hospital Pharmacy. 2008; 43:29-34.
  8. Phoxillum Product Information (PI).
  9. PrismaSol Product Information (PI).
  10. PrismaSATE Instructions for Use (IFU).
  11. PRISMAFLEX TPE 2000 Plasmafilter Instructions for Use (IFU).
  12. Luca, Bigatello et al. Critical Care Handbook of the Massachusetts General Hospital, 4th Edition, 2006.
  13. Mars Treatment Kit Instructions for Use.
  14. Karvellas et al. Crit Care. 2007;11(3):215.
  15. Hoste EA et al. Intensive Care Med. 2015;41:1411-1423.
  16. Sutherland SM, et al. Am J Kidney Dis. 2010;55:316-325.
  17. Bouchard J, et al. Kidney Int. 2009;76:422-427.
  18. Ethgen O, et al. Nephrol Dial Transplant. 2015;30:54-61.
  19. Fischer MJ, et al. Am J Kidney Dis. 2005;46:1049- 1057.
  20. Mitzner SR. Extracorporeal liver support-albumin dialysis with the molecular adsorbent recirculating system (mars). Ann Hepatol. 2011;10 Suppl 1:S21-7.
  21. Mitzner SR, Stange J, Klammt S, Koball S, Hickstein H, Reisinger EC. Albumin dialysis mars: Knowledge from 10 years of clinical investigation. Asaio j. 2009;55(5):498-502.
  22. Gurland HJ, Lysaght MH, Samtleben W, Schmidt B. Int J Artif Organs.1984;7:35-38.
  23. Gurland HJ, Lysaght MJ, Samtleben W, Schmidt B. Nephron 1984;36:173-182.
  24. Gerhardt RE, Ntoso KA, Koethe JD, et al. J Am Soc Nephrol. 1992;2:1455-1458.
  25. Frasca GM, Buscaroli A, Borgnino LC, Vangelista A. Int J Artif Organs. 1988;11:313-316.
  26. Howard RL, Tatum K, Chan L, Shapiro JI. Dial Transplant. 1990;19:484.
  27. Ilamathi E, Kirsch M, Moore B, Finger M. Semin Dial. 1993;6:268.
  28. Goldfarb DS, et al. Impending Shortages of Kidney Replacement Therapy for COVID-19 Patients. CJASN .15: 880–882, 2020. doi: https://doi.org/10.2215/CJN.05180420.
  29. Pam Harrison. COVID-19 and the Kidney: Another Target to Attack. https://www.medscape.com/viewarticle/932005#vp_2. Accessed June 15, 2020.
  30. Hepokoski ML, Malhotra A, Singh P, Crotty Alexander LE. Ventilator-Induced Kidney Injury: Are Novel Biomarkers the Key to Prevention? Nephron. 2018;140(2):90-93.
  31. Recommendations on the care of hospitalized patients with COVID-19 and kidney failure requiring renal replacement therapy. American Society of Nephrology. Release date: March 21, 2020. https://www.asn-online.org/g/blast/files/AKI_COVID-19_Recommendations_Document_03.21.2020.pdf
  32. NIH Covid-19 Treatment Guidelines. Last Updated: June 11, 2020. https://www.covid19treatmentguidelines.nih.gov/critical-care/acute-kidney-injury/
  33. Hickman, RJ. Nephrologists tackle crisis planning. ASN Kidney News. May 2020. https://www.kidneynews.org/kidney-news/features/nephrologists-tackle-crisis-planning.

Baxter, Acute Therapies Institute, Diaflux, Diamars, MARS, Marsflux, Oxiris, Phoxillum, Prismaflex, Prismaflo, Prismasate, Prismasol, Prismax, Regiocit, Thermax, and TrueVue are trademarks of Baxter International Inc. or its subsidiaries.
USMP/MG207/20-0018 09/20